Analysts expect Caladrius Biosciences, Inc. (NASDAQ:CLBS) to report $-0.83 EPS on March, 16.They anticipate $0.10 EPS change or 13.70% from last quarter’s $-0.73 EPS. After having $-0.38 EPS previously, Caladrius Biosciences, Inc.’s analysts see 118.42% EPS growth. The stock increased 0.25% or $0.01 during the last trading session, reaching $3.95. About 35,185 shares traded. Caladrius Biosciences, Inc. (NASDAQ:CLBS) has declined 9.24% since February 15, 2017 and is downtrending. It has underperformed by 25.94% the S&P500.
Trico Bancshares (NASDAQ:TCBK) had a decrease of 9.02% in short interest. TCBK’s SI was 269,400 shares in February as released by FINRA. Its down 9.02% from 296,100 shares previously. With 89,300 avg volume, 3 days are for Trico Bancshares (NASDAQ:TCBK)’s short sellers to cover TCBK’s short positions. The SI to Trico Bancshares’s float is 1.43%. The stock increased 1.28% or $0.47 during the last trading session, reaching $37.23. About 57,161 shares traded. TriCo Bancshares (NASDAQ:TCBK) has risen 30.78% since February 15, 2017 and is uptrending. It has outperformed by 14.08% the S&P500.
TriCo Bancshares operates as a bank holding firm for Tri Counties Bank that provides commercial banking services to retail clients and small to medium-sized businesses in Northern and Central California. The company has market cap of $854.65 million. It accepts demand, savings, money market rate deposit accounts, and time deposits; and provides residential and commercial real estate mortgage, consumer, commercial, agricultural, and real estate construction loans. It has a 17.24 P/E ratio. The firm also offers installment note collection services; issues cashierÂ’s checks; sells travelers checks; and provides safe deposit boxes and other customary banking services.
Investors sentiment decreased to 1.31 in Q3 2017. Its down 0.08, from 1.39 in 2017Q2. It dropped, as 9 investors sold TriCo Bancshares shares while 36 reduced holdings. 14 funds opened positions while 45 raised stakes. 15.52 million shares or 1.22% more from 15.34 million shares in 2017Q2 were reported. State Street Corporation holds 418,873 shares or 0% of its portfolio. Schwab Charles Investment Mgmt Inc owns 96,682 shares. Public Employees Retirement Association Of Colorado invested 0% in TriCo Bancshares (NASDAQ:TCBK). American Group Inc has invested 0% in TriCo Bancshares (NASDAQ:TCBK). Bnp Paribas Asset Mgmt Holding invested 0.07% in TriCo Bancshares (NASDAQ:TCBK). Legal & General Gru Public holds 5,243 shares or 0% of its portfolio. Symphony Asset Mgmt Lc accumulated 12,333 shares. Boston Limited Co accumulated 90,868 shares. Columbia Wanger Asset Management Limited Liability Co reported 236,196 shares. Bancorporation Of America De has invested 0% in TriCo Bancshares (NASDAQ:TCBK). Bnp Paribas Arbitrage stated it has 2,116 shares. Clarivest Asset Mngmt Limited holds 0.01% or 6,673 shares in its portfolio. Ironwood Mngmt Limited Com owns 0.59% invested in TriCo Bancshares (NASDAQ:TCBK) for 20,547 shares. Thomson Horstmann And Bryant has invested 0.47% in TriCo Bancshares (NASDAQ:TCBK). Rmb Management Lc has invested 0.15% in TriCo Bancshares (NASDAQ:TCBK).
Among 5 analysts covering TriCo Bancshares (NASDAQ:TCBK), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. TriCo Bancshares had 8 analyst reports since January 29, 2016 according to SRatingsIntel. Keefe Bruyette & Woods maintained it with “Hold” rating and $43.0 target in Tuesday, December 12 report. Keefe Bruyette & Woods maintained TriCo Bancshares (NASDAQ:TCBK) rating on Thursday, December 21. Keefe Bruyette & Woods has “Hold” rating and $45.0 target. The company was downgraded on Wednesday, December 13 by FIG Partners. The stock of TriCo Bancshares (NASDAQ:TCBK) earned “Market Perform” rating by Keefe Bruyette & Woods on Friday, July 29. The stock has “Hold” rating by Keefe Bruyette & Woods on Tuesday, January 30.
Since August 15, 2017, it had 0 insider buys, and 1 sale for $180,000 activity. The insider CARNEY CRAIG B sold $186,250.
Among 4 analysts covering Caladrius Biosciences (NASDAQ:CLBS), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Caladrius Biosciences had 12 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Friday, January 8 by H.C. Wainwright. The rating was initiated by Chardan Capital Markets with “Buy” on Tuesday, August 23. The stock has “Hold” rating by Maxim Group on Thursday, January 7. As per Tuesday, December 22, the company rating was maintained by Maxim Group. The company was maintained on Friday, August 11 by H.C. Wainwright. H.C. Wainwright maintained the shares of CLBS in report on Friday, July 21 with “Buy” rating. H.C. Wainwright maintained the shares of CLBS in report on Friday, January 19 with “Buy” rating. The rating was upgraded by H.C. Wainwright to “Buy” on Friday, April 29. The stock of Caladrius Biosciences, Inc. (NASDAQ:CLBS) earned “Hold” rating by Benchmark on Friday, January 8. On Wednesday, September 6 the stock rating was maintained by H.C. Wainwright with “Buy”.